NCT03825406

Prevalence of Wildtype Amyloid After TAVR

Prevalence of Wildtype Amyloid Among TAVR Patients With Impaired Hemodynamics

• Status: Withdrawn
• Phase: —
• Study type: Observational
• Enrollment: 0 (actual)
• Sponsor: North Florida Foundation for Research and Education · Academic / Other
• Sex: All
• Age: 50 Years – 100 Years
• Healthy volunteers: Not accepted

Summary

Those with abnormal vital signs after TAVR need to be willing to obtain a bone scan to evaluate for wildtype amyloidosis. Positive bone scan findings will require evaluation for primary amyloidosis with blood and urine monoclonal immunoglobulin testing. Primary amyloidosis is a different type of disease which requires different treatment.

Detailed description

This research is interested in determining how common wildtype amyloidosis is after transcatheter aortic valve replacement (TAVR). Amyloidosis is a condition characterized by abnormal protein which can accumulate and impair various organs, including the heart. Research suggests that amyloidosis might be common among TAVR patients, but it is a condition that is not routinely evaluated for. We suspect that wildtype amyloidosis may be especially common among patients with abnormal vital signs after their TAVR procedure.

Conditions

• Amyloidosis

Timeline

• Start date: 2019-03-20
• Primary completion: 2019-03-20
• Completion: 2019-03-20
• First posted: 2019-01-31
• Last updated: 2019-03-22